Skip to main content
. 2020 Feb 14;9(3):148–156. doi: 10.1159/000505873

Table 1.

Characteristics of participants

Euthyroid controls (n = 55) Graves' disease (n = 55) p value
Female, n (%) 45 (82) 45 (82) 1.00
Age, years 40±14 40±14 0.97
Height, cm 170±9 170±9 0.73
Weight, kg 66.8 (61.1 to 79.1) 67.7 (60.2 to 83.4) 0.84
BMI, kg/m2 23.5 (21.6 to 25.8) 24.7 (20.3 to 27.3) 0.83
Hypertension, n (%)a 6 (10.9) 8 (14.6) 0.57
Current smokers, n (%) 6 (10.9) 9 (16.4) 0.41

Biochemistryb
Thyrotropin, IU/L 2.2 (1.5 to 3.2) 0.0 (0.0 to 0.0) <0.0001
Free triiodothyronine, pmol/L 4.8 (4.6 to 5.1) 11.6 (8.0 to 15.8) <0.0001
Free thyroxine, pmol/L 15.1 (14.1 to 16.6) 32.3 (24.9 to 41.9) <0.0001
TRAb, IU/L <0.9 9.3 (4.8 to 15.4) <0.0001
Cholesterol, mmol/L 4.7±0.9 4.1±0.8 <0.001
LDL, mmol/L 2.6±0.8 2.1±0.7 <0.001
HDL, mmol/L 1.7±0.5 1.5±0.5 <0.05
Triglyceride, mmol/Lb 0.8 (0.6 to 1.0) 1.0 (0.8 to 1.3) <0.001

Numbers (n) with percentage (%), mean ± standard deviation or median with interquartile range.

a

Hypertension diagnosed prior to enrollment.

b

Reference ranges: thyrotropin 0.3–4.5; free triiodothyronine 3.9–6.8; free thyroxine 12–21; thyrotropin receptor antibody (TRAb) <1.75; total cholesterol <5.0; low-density lipoprotein (LDL) cholesterol <3.0; high-density lipoprotein (HDL) cholesterol >1.2 (women); triglyceride <2.0.